CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Self-Compassion for Chronic Pain Virtual Group Treatment ProgramWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug800 Duvelisib Wiki 1.00
drug1795 Peripheral blood draw Wiki 0.71
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D059350 Chronic Pain NIH 0.41

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0012532 Chronic pain HPO 0.41

There is one clinical trial.

Clinical Trials

1 A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery

As a result of COVID-19 and measures taken by the Canadian Government to reduce the transmission of the virus, in-person psychology services have been suspended. Psychology services are now being conducted via video conferencing. The purpose of the current project is to pilot-test a 6-week Self Compassion Treatment for Chronic Pain delivered virtually, in order to understand its utility in the current environment. The treatment is to be delivered through a secure professional ZOOM licence. Objective 1 of the project is to assess the feasibility and acceptability of attending the treatment group through virtual participation. Objective 2 is to assess the effectiveness of the group treatment in improving self-compassion, mental health, relationship with pain, and quality of life.

NCT04413006 Chronic Pain Behavioral: Self-Compassion for Chronic Pain Virtual Group Treatment Program
MeSH:Chronic Pain
HPO:Chronic pain

Primary Outcomes

Description: Change over time in scores on the Self-Compassion Scale (SCS) (score range is 12-60 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Self-Compassion Scale (SCS)

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Pain Disability Index (score range is 0-70 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Pain Disability Index

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Secondary Outcomes

Description: Change over time in scores on the on the Chronic Pain Acceptance Questionnaire - 8 (CPAQ-8) (score range is 0-48 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Chronic Pain Acceptance Questionnaire - 8

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the on the Pain Catastrophizing Scale-6 (PCS-6) (score range is 0-24 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Pain Catastrophizing Scale -6

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 (PSEQ-4) (score range is 0-24 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Numeric Rating Scale (NRS) for pain (score range is 0-10 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Pain Intensity

Time: at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Patient Health Questionnaire-9 (PHQ-9) (score range is 0-27 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Depression Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Generalized Anxiety Scale (GAD-7) (score range is 0-21 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Changes over time in Anxiety Symptoms as measured by the Generalized Anxiety Scale-7

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Physical Health and Mental Health Quality of Life scores from the PROMIS GLOBAL-10 (score range is 7-35 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Quality of Life as measured by the PROMIS GLOBAL- 10

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Changes over time in score on the Mindfulness Attention and Awareness Scale (MAAS) (score range is 15-90 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Changes over time in Mindfulness

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Other Outcomes

Description: Scores on the Client Satisfaction Questionnaire

Measure: Client Satisfaction

Time: post treatment (6 weeks after beginning the treatment)

Related HPO nodes (Using clinical trials)

HP:0012532: Chronic pain
Genes 3
TGFB2 ATXN3 FLVCR1
Protein Mutations 1
K15210D
SNP 2
rs1042713 rs12654788